Shots:

• The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC- 40-80mg) vs PBO in 105 patients with hypertriglyceridemia- T2D- and NAFLD for 6mos.
• The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides- ANGPTL3- apoC-III- VLDL-C- non-HDL cholesterol- no reduction in liver fat and is well tolerated
• AKCEA-ANGPTL3-L_Rx is an investigational antisense therapy- designed to reduce the production of ANGPTL3. Additionally- in 2019- Akcea signed a WW exclusive license agreement with Pfizer for the therapy under which Pfizer is responsible for all development and regulatory activities and costs beyond those associated with P-II study

Click here ­to­ read full press release/ article | Ref: Akcea | Image: Akcea